<p>/PRNewswire/ -- LakeShore Biopharma Co., Ltd（&#34;LakeShore Biopharma&#34;或&#34;公司&#34;）（OTCPK: LSBCF; OTCPK: LSBWF），是一家全球生物制药公司，致力于发现、开发、生产和交付新一代针对传染病和癌症的疫苗和治疗性生物制剂。今天宣布，公司于 2026 年 2 月 4 日收到来自一个由 Oceanpine Skyline Inc.（&#34;母公司&#34;）、Oceanpine Merger Sub Inc.（&#34;合并子公司&#34;）、Oceanpine Capital Inc.、Oceanpine Investment Fund II LP、Crystal Peak Investment Inc.、Adjuvant Global Health Technology Fund, L.P.、Adjuvant Global Health Technology Fund DE, L.P.、Superstring Capital Master Fund LP、MSA GROWTH FUND II, L.P.和 Epiphron Capital (Hong Kong) Limited 组成的买方集团（&#34;买方集团&#34;）的通知，涉及公司之前宣布的私有化交易，买方集团同意根据 2025 年 11 月 4 日公司、母公司和合并子公司之间签署的合并协议（&#34;合并协议&#34;），以每股 0.90 美元的价格将公司私有化。</p>
<p>根据该通知，买方集团声称公司于 2026 年 1 月 21 日和 1 月 22 日从开封仲裁委员会收到的仲裁裁决——该裁决已在公司于 2026 年 1 月 29 日向证券交易委员会（&#34;SEC&#34;）提交的 6-K 表格当前报告中披露——以及由此产生的约人民币 576,500,000 的财务责任构成了合并协议下的&#34;公司重大不利影响&#34;。</p>
<p>买方集团声称，母公司完成合并（如合并协议中定义）的前提条件是未发生公司重大不利影响（如合并协议中定义），而买方集团已确定发生了公司重大不利影响，因此买方集团有权不完成合并。买方集团表示，它将不参加或投票即将于 2026 年 2 月 12 日举行的特别股东大会（&#34;EGM&#34;），该会议将考虑并投票通过包括授权和批准合并协议、需向开曼群岛公司注册处提交的合并计划及相关交易（包括合并）在内的事项。</p>
<p>买方集团表示愿意与公司进行善意讨论，以探索修改交易条款的可能性，以促进达成双方都能接受的解决方案并成功完成交易。</p>
<p>鉴于这一发展，公司决定推迟之前宣布的 EGM。已提交给公司的任何关于 EGM 的代理卡将被忽略。截止到 2026 年 1 月 16 日下午 5 点（开曼群岛时间）的股东将各自收到关于 EGM 推迟的通知。该通知也将在公司网站 https://investors.lakeshorebio.com/index.html 和 SEC 网站 http://www.sec.gov 上发布。</p>
<p>公司将仔细审查和评估买方集团的主张及公司的选择，并将根据适用法律的要求提供进一步的更新。</p>
<p><strong>关于 LakeShore Biopharma Co., Ltd</strong></p>
<p>LakeShore Biopharma，之前称为 YS Biopharma，是一家全球生物制药公司，致力于发现、开发、生产和交付新一代针对传染病和癌症的疫苗和治疗性生物制剂。它开发了专有的 PIKA®免疫调节技术平台和针对狂犬病、乙型肝炎、流感及其他病毒感染的新一代预防和治疗性生物制剂。公司在中国、新加坡和菲律宾运营，由一支结合丰富本地专业知识和全球生物制药行业经验的管理团队领导。</p>
<p>欲了解更多信息，请访问 https://investors.lakeshorebio.com/.</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含可能构成 “前瞻性” 声明的内容。这些前瞻性声明包括但不限于公司的商业计划和发展，可以通过诸如 “可能”、“将”、“期望”、“预期”、“目标”、“未来”、“估计”、“打算”、“计划”、“相信”、“潜在”、“继续”、“可能会” 等术语或其他类似表达来识别。LakeShore Biopharma 还可能在其定期向美国证券交易委员会（SEC）提交的报告、年度股东报告、新闻稿及其他书面材料中，以及其高管、董事或员工向第三方所作的口头声明中作出书面或口头的前瞻性声明。那些不是历史事实的声明，包括关于 LakeShore Biopharma 的信念、计划和期望的声明，均为前瞻性声明。前瞻性声明涉及固有的风险和不确定性。一些因素可能导致实际结果与任何前瞻性声明中包含的结果存在重大差异，包括但不限于以下因素：可能出现导致合并协议终止或修订的事件；可能会提出竞争性报价；融资可能不可用的可能性；交易的各种成交条件可能无法满足或被放弃的可能性；以及公司向 SEC 提交的文件中讨论的其他风险和不确定性，以及公司提交的 Schedule 13E-3 和代理声明；公司的目标和战略；公司的未来业务发展、财务状况和经营成果；其提供高效服务和有效竞争的能力；其维护和提升品牌认知度和声誉的能力；全球及中国的一般经济和商业状况，以及与上述任何内容相关的假设。有关这些及其他风险、不确定性或因素的进一步信息包含在公司向 SEC 提交的文件中。本新闻稿中提供的所有信息均截至本新闻稿的日期，公司不承担因新信息、未来事件或其他原因而更新任何前瞻性声明的义务，除非适用法律要求。</p>
<p><strong>如需投资者咨询，请联系：</strong></p>
<p><strong>投资者关系团队</strong> 电话：+86 (10) 8920-2086</p>
<p>电子邮件：[email protected]</p>
<p>来源：LakeShore Biopharma Co., Ltd.</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjA2Jk5ld3NJdGVtSWQ9Q044MjQ4OCZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMDYwNzAwUFJfTkVXU19VU1BSX19fX19DTjgyNDg4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjA2Jk5ld3NJdGVtSWQ9Q044MjQ4OCZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMDYwNzAwUFJfTkVXU19VU1BSX19fX19DTjgyNDg4"/></p>

LSBCF

<p>LakeShore Biopharma 收到了买方集团关于以每股 0.90 美元进行私有化交易的通知。买方集团声称，最近的仲裁裁决导致约 5.765 亿人民币的财务负担，构成了 “公司重大不利影响”，使他们能够退出合并。因此，原定于 2026 年 2 月 12 日的特别股东大会已被推迟。公司将审查这些主张，并在必要时提供更新</p>

<p>, /PRNewswire/ -- LakeShore Biopharma Co., Ltd (&#34;LakeShore Biopharma&#34; or the &#34;Company&#34;) (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has received a notice, dated February 4, 2026, from legal counsel to a group (the &#34;Buyer Group&#34;) consisting of Oceanpine Skyline Inc. (&#34;Parent&#34;), Oceanpine Merger Sub Inc. (&#34;Merger Sub&#34;), Oceanpine Capital Inc., Oceanpine Investment Fund II LP, Crystal Peak Investment Inc., Adjuvant Global Health Technology Fund, L.P., Adjuvant Global Health Technology Fund DE, L.P., Superstring Capital Master Fund LP, MSA GROWTH FUND II, L.P., and Epiphron Capital (Hong Kong) Limited, relating to the previously announced going-private transaction of the Company whereby the Buyer Group agreed to take the Company private at a price of $0.90 per share pursuant to an Agreement and Plan of Merger (the &#34;Merger Agreement&#34;), dated November 4, 2025, by and among the Company, Parent and Merger Sub.</p>
<div class="lb-trans"><p>/PRNewswire/ -- LakeShore Biopharma Co., Ltd（&#34;LakeShore Biopharma&#34;或&#34;公司&#34;）（OTCPK: LSBCF; OTCPK: LSBWF），是一家全球生物制药公司，致力于发现、开发、生产和交付新一代针对传染病和癌症的疫苗和治疗性生物制剂。今天宣布，公司于 2026 年 2 月 4 日收到来自一个由 Oceanpine Skyline Inc.（&#34;母公司&#34;）、Oceanpine Merger Sub Inc.（&#34;合并子公司&#34;）、Oceanpine Capital Inc.、Oceanpine Investment Fund II LP、Crystal Peak Investment Inc.、Adjuvant Global Health Technology Fund, L.P.、Adjuvant Global Health Technology Fund DE, L.P.、Superstring Capital Master Fund LP、MSA GROWTH FUND II, L.P.和 Epiphron Capital (Hong Kong) Limited 组成的买方集团（&#34;买方集团&#34;）的通知，涉及公司之前宣布的私有化交易，买方集团同意根据 2025 年 11 月 4 日公司、母公司和合并子公司之间签署的合并协议（&#34;合并协议&#34;），以每股 0.90 美元的价格将公司私有化。</p>
</div><p>According to the notice, the Buyer Group asserted that the arbitral awards received by the Company from the Kaifeng Arbitration Commission on January 21 and January 22, 2026—previously disclosed in the Company's current report on Form 6-K furnished with the Securities and Exchange Commission (the &#34;SEC&#34;) on January 29, 2026—and the resulting financial liability of approximately RMB576,500,000 constitute a &#34;Company Material Adverse Effect&#34; under the Merger Agreement.</p>
<div class="lb-trans"><p>根据该通知，买方集团声称公司于 2026 年 1 月 21 日和 1 月 22 日从开封仲裁委员会收到的仲裁裁决——该裁决已在公司于 2026 年 1 月 29 日向证券交易委员会（&#34;SEC&#34;）提交的 6-K 表格当前报告中披露——以及由此产生的约人民币 576,500,000 的财务责任构成了合并协议下的&#34;公司重大不利影响&#34;。</p>
</div><p>The Buyer Group asserted that a condition precedent to Parent's obligation to close the Merger (as defined in the Merger Agreement) is that no Company Material Adverse Effect (as defined in the Merger Agreement) shall have occurred, and the Buyer Group has determined that a Company Material Adverse Effect has occurred and that the Buyer Group has the right not to consummate the Merger. The Buyer Group indicated that it would not attend or cast votes at the upcoming extraordinary general meeting (the &#34;EGM&#34;), scheduled for February 12, 2026, to consider and vote on, among other matters, the proposal to authorize and approve the Merger Agreement, the plan of merger required to be filed with the Registrar of Companies of the Cayman Islands, and the transactions contemplated thereby, including the Merger.</p>
<div class="lb-trans"><p>买方集团声称，母公司完成合并（如合并协议中定义）的前提条件是未发生公司重大不利影响（如合并协议中定义），而买方集团已确定发生了公司重大不利影响，因此买方集团有权不完成合并。买方集团表示，它将不参加或投票即将于 2026 年 2 月 12 日举行的特别股东大会（&#34;EGM&#34;），该会议将考虑并投票通过包括授权和批准合并协议、需向开曼群岛公司注册处提交的合并计划及相关交易（包括合并）在内的事项。</p>
</div><p>The Buyer Group expressed its willingness to engage in good faith discussions with the Company to explore amendments to the transaction terms to facilitate a mutually acceptable resolution and the successful completion of the transaction.</p>
<div class="lb-trans"><p>买方集团表示愿意与公司进行善意讨论，以探索修改交易条款的可能性，以促进达成双方都能接受的解决方案并成功完成交易。</p>
</div><p>In light of this development, the Company has decided to postpone the previously announced EGM. Any proxy cards that have been submitted to the Company in respect of the EGM will be disregarded. Shareholders of record as of 5 p.m. Cayman Islands time on January 16, 2026 will each receive a copy of the notice regarding the postponement of the EGM. The notice will also be available on the Company's website at https://investors.lakeshorebio.com/index.html and on the SEC's website at http://www.sec.gov.</p>
<div class="lb-trans"><p>鉴于这一发展，公司决定推迟之前宣布的 EGM。已提交给公司的任何关于 EGM 的代理卡将被忽略。截止到 2026 年 1 月 16 日下午 5 点（开曼群岛时间）的股东将各自收到关于 EGM 推迟的通知。该通知也将在公司网站 https://investors.lakeshorebio.com/index.html 和 SEC 网站 http://www.sec.gov 上发布。</p>
</div><p>The Company will carefully review and evaluate the Buyer Group's claims and the Company's options, and will provide further updates as required under applicable law.</p>
<div class="lb-trans"><p>公司将仔细审查和评估买方集团的主张及公司的选择，并将根据适用法律的要求提供进一步的更新。</p>
</div><p><strong>About LakeShore Biopharma Co., Ltd</strong></p>
<div class="lb-trans"><p><strong>关于 LakeShore Biopharma Co., Ltd</strong></p>
</div><p>LakeShore Biopharma, previously known as YS Biopharma, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Hepatitis B, Influenza, and other virus infections. The Company operates in China, Singapore, and the Philippines, and is led by a management team that combines rich local expertise and global experience in the biopharmaceutical industry.</p>
<div class="lb-trans"><p>LakeShore Biopharma，之前称为 YS Biopharma，是一家全球生物制药公司，致力于发现、开发、生产和交付新一代针对传染病和癌症的疫苗和治疗性生物制剂。它开发了专有的 PIKA®免疫调节技术平台和针对狂犬病、乙型肝炎、流感及其他病毒感染的新一代预防和治疗性生物制剂。公司在中国、新加坡和菲律宾运营，由一支结合丰富本地专业知识和全球生物制药行业经验的管理团队领导。</p>
</div><p>For more information, please visit https://investors.lakeshorebio.com/.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 https://investors.lakeshorebio.com/.</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains statements that may constitute &#34;forward-looking&#34; statements. These forward-looking statements include, without limitation, the Company's business plans and development, which can be identified by terminology such as &#34;may,&#34; &#34;will,&#34; &#34;expect,&#34; &#34;anticipate,&#34; &#34;aim,&#34; &#34;future,&#34; &#34;estimate,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;believe,&#34; &#34;potential,&#34; &#34;continue,&#34; &#34;is/are likely to&#34; or other similar expressions. LakeShore Biopharma may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about LakeShore Biopharma's beliefs, plans and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the possibility that events may arise that result in the termination or amendment of the Merger Agreement; the possibility that competing offers will be made; the possibility that financing may not be available; the possibility that various closing conditions for the transaction may not be satisfied or waived; and other risks and uncertainties discussed in documents filed with the SEC by the Company, as well as the Schedule 13E-3 and the proxy statement filed by the Company; the Company's goals and strategies; the Company's future business development, financial condition and results of operations; its ability to provide efficient services and compete effectively; its ability to maintain and enhance the recognition and reputation of its brands; general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.</p>
<div class="lb-trans"><p>本新闻稿包含可能构成 “前瞻性” 声明的内容。这些前瞻性声明包括但不限于公司的商业计划和发展，可以通过诸如 “可能”、“将”、“期望”、“预期”、“目标”、“未来”、“估计”、“打算”、“计划”、“相信”、“潜在”、“继续”、“可能会” 等术语或其他类似表达来识别。LakeShore Biopharma 还可能在其定期向美国证券交易委员会（SEC）提交的报告、年度股东报告、新闻稿及其他书面材料中，以及其高管、董事或员工向第三方所作的口头声明中作出书面或口头的前瞻性声明。那些不是历史事实的声明，包括关于 LakeShore Biopharma 的信念、计划和期望的声明，均为前瞻性声明。前瞻性声明涉及固有的风险和不确定性。一些因素可能导致实际结果与任何前瞻性声明中包含的结果存在重大差异，包括但不限于以下因素：可能出现导致合并协议终止或修订的事件；可能会提出竞争性报价；融资可能不可用的可能性；交易的各种成交条件可能无法满足或被放弃的可能性；以及公司向 SEC 提交的文件中讨论的其他风险和不确定性，以及公司提交的 Schedule 13E-3 和代理声明；公司的目标和战略；公司的未来业务发展、财务状况和经营成果；其提供高效服务和有效竞争的能力；其维护和提升品牌认知度和声誉的能力；全球及中国的一般经济和商业状况，以及与上述任何内容相关的假设。有关这些及其他风险、不确定性或因素的进一步信息包含在公司向 SEC 提交的文件中。本新闻稿中提供的所有信息均截至本新闻稿的日期，公司不承担因新信息、未来事件或其他原因而更新任何前瞻性声明的义务，除非适用法律要求。</p>
</div><p><strong>For investor inquiries, please contact:</strong></p>
<div class="lb-trans"><p><strong>如需投资者咨询，请联系：</strong></p>
</div><p><strong>IR Team</strong> Tel: +86 (10) 8920-2086</p>
<div class="lb-trans"><p><strong>投资者关系团队</strong> 电话：+86 (10) 8920-2086</p>
</div><p>Email: [email protected]</p>
<div class="lb-trans"><p>电子邮件：[email protected]</p>
</div><p>SOURCE LakeShore Biopharma Co., Ltd.</p>
<div class="lb-trans"><p>来源：LakeShore Biopharma Co., Ltd.</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjA2Jk5ld3NJdGVtSWQ9Q044MjQ4OCZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMDYwNzAwUFJfTkVXU19VU1BSX19fX19DTjgyNDg4" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CN82488&amp;Transmission_Id=202602060700PR_NEWS_USPR_____CN82488&amp;DateId=20260206"/></p>

LakeShore Biopharma 宣布已收到买方团体的通知，并推迟了股东特别大会